FDA Commissioner envisions fewer delays, more clinical trial flexibility and AI use
US Food and Drug Administration (FDA) Commissioner Dr. Marty Makary addressed concerns about the recent cuts impacting the agency’s ability…
All articles by Manasi Vaidya
Manasi Vaidya
@manasivaidya22
Manasi Vaidya is an editor for GlobalData Insights where she covers the healthcare space. She writes and edits features that look at the research, regulation and reimbursement of drugs with a focus on topics at the intersection of business and science.
-
-
FDA creates new priority review voucher scheme to boost US interests
The US Food and Drug Administration (FDA) has created a new priority review voucher (PRV) framework to expedite the drug…
-
European biotech ecosystem takes aim at changing the funding narrative
“The science is brilliant in Europe, but the translation is what’s lacking,” said V-Bio Ventures managing partner Christina Takke on…
-
Trump’s first 100 days tout US-bound pharma investments amid tariff worries
Pharma companies are looking to shore up manufacturing operations in the US to counter international tariffs, but are also bracing…
-
Podcast: What’s next for pharma tariffs?
The US government has signalled a major shift in its trade policies in recent weeks, with several announcements detailing plans…
-
Eli Lilly targets Scorpion Therapeutics to expand reach in oncology
Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away…
-
Trump picks vaccine sceptic RFK Jr to lead HHS in new administration
President-elect Donald Trump has appointed Robert F Kennedy Jr, popularly known as RFK Jr, as the secretary of the premier…
-
Magazine: UK’s new Netflix-style funding model for antibiotics goes live
After trialling a subscription-style system for procuring antimicrobial drugs, the UK’s National Health Service recently announced that it will formalise…
-
European pharma regulation changes signal tumult and transformation
The ongoing European Union (EU) elections, a revision of key legislation governing the pharmaceutical and biotech industry in Europe, and…
-
Data needed to forge the link between AI and mRNA
Tackling two of the buzziest trends in pharma right now; AI and mRNA therapeutics, is high on the agenda of…